Re: Crusty Fat FacesOn Apr 24, 1:40 pm, ironjustice <teamtan...@hotmail,com > wrote:
migraines .. ? <<
Is it mere coincidence they give you a drug which lowers the red blood
cell count and it replaces oxygen ..
"Acetacolamide or oxygen"
Therefore it would NOW make .. sense .. that bloodletting allows one
to .. breathe .. better.
Bloodletting lowers red blood cell .. count.
It is also used for polycythemia / increased red blood cell count and
they get .. migraines.
Prevalence of Migraine in Patients with
Systemic Lupus Erythematosus
Glanz BL, Venkatesan A, Schur PH, et al.
Posted: May 2003
Headache 2001;41:285-289
--------------------------------------------------------------------------------
Objective: To determine the prevalence of migraine in patients with
systemic lupus erythematosus (SLE), and to examine the relationships
between headache type and other clinical, serologic, and treatment
features of the disease.
Background: Headaches are common in SLE and are a significant source
of patient disability. The exact prevalence of headaches in patients
with SLE is unknown. The classification of headache syndromes in SLE
is also unclear. Previous studies were based on small numbers of
patients and the headache types and criteria to define headache types
varied widely.
Methods: The study involved 414 patients meeting American College of
Rheumatology criteria for the diagnosis of SLE who were sent the
University of California, San Diego Migraine Questionnaire. Patients
who completed the questionnaire had their medical records reviewed for
constitutional, respiratory, cardiac, vascular, skin, musculoskeletal,
other neuropsychiatric, hematologic, renal, and immunologic
manifestations of the disease. Recent corticosteroid, nonsteroidal
anti-inflammatory drug, antimalarial, and immunosuppressive
medications were also recorded.
Results: The questionnaire was completed by 186 patients. Sixty-two
percent of patients reported headaches: 39 percent met diagnostic
criteria for migraine and 23 percent met criteria for non-migrainous
headache. Of the patients with migraine, 56 percent met criteria for
migraine without aura and 44 percent met criteria for migraine with
aura. There were no significant associations between headache type and
other clinical, serologic, or treatment features of the disease.
Conclusions: There is a high prevalence of migraine in patients with
SLE, and patients should be routinely evaluated for migraine
symptoms.
> On Apr 24, 12:53 pm, ironjustice <teamtan...@hotmail,com > wrote:
>
> Anybody care to try to explain why sleep apnea is treated with the
> high altitude drug .. ?
> And also try to explain why they are all linked to migraine .. ?
>
> Anybody with lupus get .. migraines .. ?
>
> And again maybe explain why people with erythrocytosis get sleep
> apnea .. ?
>
> "Acetacolamide or oxygen"
>
> Sanner B, Schäfer T
> [Central sleep apnea syndrome] [English Abstract, Journal Article,
> Review]
> Dtsch Med Wochenschr 2008 Apr; 133(14):722-6.
>
> Central sleep apnea (CSA) is characterized by a lack of drive to
> inspire for at least 10 sec. In the CSA-syndrome accompanying arousals
> and desaturations of the arterial blood cause sleep disturbances and
> sympathetic nerve activations which lead to excessive daytime
> sleepiness and increase the risk for cardiovascular morbidity. There
> are six manifestations of CSA: a rare primary or idiopathic form,
> often in hypocapnic patients with an increased hypercapnic ventilatory
> drive; Cheyne-Stokes respiration, characterised by periodic CSA and a
> crescendo/decrescendo breathing pattern, often in patients with severe
> cardiac or neurological diseases; high altitude-induced periodic
> breathing (above 4000 m), CSA due to medical or neurological
> conditions; CSA due to drug or substance use; and primary sleep apnea
> of infancy. Besides the consequent treatment of the underlying medical
> conditions therapeutic options include the use of drugs, e. g.
> acetacolamide or oxygen, as well as non-invasive ventilation, e. g.
> continuous positive airway pressure (CPAP) or adaptive servo-
> ventilation.
>
> --------------------------------------------
>
> Migraine Linked to Sleep Apnea in Children and Teens
>
> Kathleen Louden
> Information from Industry
> NAMENDA® (memantine HCl) –– The first and only NMDA–receptor
> antagonist for the treatment of moderate to severe Alzheimer's
> disease. NAMENDA has been used by over 2 million patients
> worldwide.Read Important Safety Information and Prescribing
> Information.
>
> April 22, 2008 (Chicago, Illinois) — In children and teenagers with
> both headaches and sleep complaints, a new study using polysomnography
> showed an association between migraine and sleep-disordered breathing
> and between tension headache and bruxism.
>
> Patients in this study were evaluated at St. Christopher Hospital for
> Children, Drexel University, in Philadelphia, Pennsylvania. Ninety
> patients with headache and sleep problems aged 5 to 19 years underwent
> polysomnography, an electroencephalography-based sleep test. Migraine
> was the most common type of headache, occurring in 60 of the 90
> patients. Another 11 patients had chronic daily headache, 6 had
> tension headache, and 13 had nonspecific headache, such as morning
> headache. Sleep-disordered breathing, including obstructive sleep
> apnea, was about twice as common in the migraineurs as in patients
> with other types of headache (56% vs 30%, respectively), the authors
> found.
>
> "Parents and doctors need to be aware of the strong likelihood of
> sleep disorders in children with migraine," said lead author Martina
> Vendrame, MD, PhD, from the department of neurology at Temple
> University, also in Philadelphia.
>
> Dr. Vendrame presented the results at the American Academy of
> Neurology (AAN) 60th Annual Meeting.
>
> Ask About Sleep
>
> A neurologist who did not participate in the study called it "a good
> step in recognizing the broad reach of disordered sleep." Bradley V.
> Vaughn, MD, professor of neurology at the University of North Carolina
> at Chapel Hill, moderated the highlights session on sleep disorders at
> the meeting.
>
> "Children with headache should be questioned about symptoms of sleep
> disorders because there's a high incidence of them in this group," Dr.
> Vaughn told Medscape Neurology & Neurosurgery.
>
> During a press briefing, Dr. Vendrame said physicians should ask
> parents of children with migraine about snoring, frequent awakening
> during sleep, and daytime sleepiness.
>
> When asked whether the fact that all of their patients had reported
> sleep problems could have biased the study results, Dr. Vendrame
> agreed it was possible. She told Medscape Neurology & Neurosurgery,
> "We want to repeat the study in a general population of children or in
> children who have headache but do not report sleep complaints."
>
> However, polysomnograms showed disturbed sleep architecture in the
> study patients with severe migraine and with chronic daily headache
> (occurring more than 15 days a month). These children and teens took a
> longer time to fall asleep, had shorter rapid eye movement (REM)
> sleep, and slept less total time than did those with milder or less
> frequent migraine, she reported.
>
> "Children with migraines take naps, and that can affect sleep
> architecture," Dr. Vendrame said at the press conference. "But
> headache may contribute to sleep disorders in children. We think they
> share common mechanisms, which may be related to REM sleep."
>
> The authors observed other sleep disturbances. Three (50%) of the
> patients with tension headache had bruxism, whereas only 2.4% of the
> patients with other types of headache ground their teeth during sleep,
> according to the abstract.
>
> Referral
>
> "Teeth grinding is related to dysfunction of the temporomandibular
> joint, and these children need to be referred to a dental specialist,"
> Dr. Vendrame said.
>
> Most of the children with sleep apnea needed referral to an ear-nose-
> throat (ENT) specialist, and about 50% of those children underwent
> tonsillectomy, the author said. "After surgery, about 80% had less
> severe and less frequent migraine," she said. "This needs more follow-
> up."
>
> American Academy of Pediatrics guidelines for children with symptoms
> of sleep disorders are to refer them for a sleep study, according to
> Dr. Vaughn. "However, there are not as many sleep centers that do
> sleep studies in children as there are for adults," he said. "As a
> backup plan, have an ENT evaluate the child."
>
> Polysomnography is not part of the usual migraine workup in children.
> The sleep test monitors the brain, eye movements, breathing, cardiac
> rhythm, and muscle activity.
>
> Drs. Vendrame and Vaughn report no relevant financial disclosures.
>
> American Academy of Neurology 60th Annual Meeting: Abstract S49.008.
> Presented April 17, 2008
> --------------------------------------------------------------------------------
>
> Kathleen Louden is a freelance writer for Medscape.
>
> Medscape Medical News 2008. © 2008 Medscape
>
> Who loves ya.
> Tom
>
> Jesus Was A Vegetarian! http :// tinyurl,com /2r2nkh
>
> Man Is A Herbivore! http :// tinyurl,com /a3cc3
>
> DEAD PEOPLE WALKING http :// tinyurl,com /zk9fk
>
>
>
> > On Apr 24, 7:41 am, ironjustice <teamtan...@hotmail,com > wrote:high
> > altitude <<
>
> > What is the significance this person is put on Diamox /
> > Acetazolamide .. a drug SPECIFICALLY used for high altitude
> > sickness .. ?
>
> > http :// brain.hastypastry,net /forums/archive/index.php/t-494.html
>
> > "I have/had pseudotumor cerebri. I was diagnosed with it last year,
> > and put on diamox. Mine is specifically related to lupus, and only
> > occurs during a severe lupus flare."
> > ----------------------------------
>
> > "Excessive erythrocytosis"
>
> > Published ahead of print on April 3, 2008
> > Am. J. Respir. Crit. Care Med. 2008, doi:10.1164/rccm.200802-196OC
>
> > Acetazolamide for Monge's Disease: Efficiency and Tolerance of a 6
> > Month Treatment
> > Jean-Paul Richalet1*, Maria Rivera-Ch2, Maxime Maignan3, Catherine
> > Privat2, Isabelle Pham4, Jose-Luis Macarlupu2, Olivier Petitjean5,
> > and
> > Fabiola Leon-Velarde2
> > 1 Laboratorie "Reponses cellulaires et fonctionnelles a l'hypoxie,"
> > EA2363, ARPE, UFR SMBH, Universite Paris 13, Bobigny, France; Service
> > de Physiologie et Explorations Fonctionnelles, Service de Pharmacie,
> > AP-HP, hopital Avicenne, Bobigny, France, 2 Facultdad de Ciencias y
> > Filosofia, Dpto. De Ciencias Biologicas y Fisiologicas, Laboratorio
> > de
> > Fisiologia Comparada, Universidad Peruana Cayetano Heredia, Lima,
> > Peru, 3 Laboratorie "Reponses cellulaires et fonctionnelles a
> > l'hypoxie," EA2363, ARPE, UFR SMBH, Universite Paris 13, Bobigny,
> > France; pole Urgences, CHU Grenoble, La Tronche, France, 4
> > Laboratorie
> > "Reponses cellulaires et fonctionnelles a l'hypoxie," EA2363, ARPE,
> > UFR SMBH, Universite Paris 13, Bobigny, France; Service de
> > Physiologie
> > et Explorations Fonctionnelles, AP-HP, hopital Jean Verdier, Bondy,
> > France, 5 Service de Physiologie et Explorations Fonctionnelles,
> > Service de Pharmacie, AP-HP, hopital Avicenne, Bobigny, France
>
> > * To whom correspondence should be addressed. E-mail:
> > richa...@smbh.univ-paris13,fr .
>
> > Rationale:
> > Monge's disease is characterized by an excessive erythrocytosis,
> > frequently associated with pulmonary hypertension, in high altitude
> > dwellers. It has a considerable impact on public health in high
> > altitude regions. A preliminary study demonstrated the efficiency of
> > acetazolamide (250 mg/day for 3 weeks) in reducing serum
> > erythropoietin and hematocrit.
> > Objectives:
> > Evaluate the efficacy and tolerance of a 6-month treatment with 250
> > mg
> > acetazolamide that could be chronically implemented and its effects
> > on
> > pulmonary artery pressure and cardiac function.
> > Methods:
> > A two-phase study was performed in patients (hematocrit 63%) from
> > Cerro de Pasco, Peru (4,300 m). First phase: a double blind placebo-
> > controlled study in 55 patients who receive a single dose of either
> > 250mg acetazolamide (n=40) or placebo (n=15) by daily oral
> > administration for twelve weeks. Second phase (open label): after a
> > four-week wash out period, all patients received 250mg acetazolamide
> > for twelve weeks. Hematocrit, blood gases, clinical outcome and
> > pulmonary artery circulation were evaluated.
> > Results:
> > First phase: acetazolamide decreased by 44% the number of
> > polycythemic
> > subjects (p=0.02), decreased hematocrit from 69 to 64% (p<0.001) and
> > increased arterial O2 pressure from 42 to 45 mmHg (p<0.001). No
> > severe
> > adverse effect, nor hypokalemia was recorded. The second
>
> ...
>
> read more »- Hide quoted text -
>
> - Show quoted text -